Physician profile
Madeline L Singer
NPI 1013369131
$15,698.69
in general payments reported to CMS, 2019-2025
15 companies · $13K in 2025
The $13K reported for 2025 was more than what 82% of Neuromuscular Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $545 · 2023: $582 · 2024: $1,852 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,680 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,774 · Food and Beverage: $2,772 · Travel and Lodging: $928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,680.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,774.00 |
| Food and Beverage | $2,772.39 |
| Travel and Lodging | $927.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $5,341.10 | 2023-2025 | Hyqvia |
| Alexion Pharmaceuticals, INC. | $3,753.34 | 2022-2025 | Ultomiris |
| Janssen Biotech, INC. | $3,350.35 | 2025 | |
| Janssen Scientific Affairs, LLC | $935.16 | 2024-2025 | |
| Ucb, INC. | $731.55 | 2022-2025 | Bimzelx, Rystiggo, Zilbrysq |
| Argenx US, INC. | $450.92 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Genzyme Corporation | $428.45 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $214.68 | 2024-2025 | Amvuttra, Onpattro |
| Biogen, INC. | $149.30 | 2024 | Spinraza |
| Amgen INC. | $147.94 | 2025 | Uplizna |
| Csl Behring | $102.43 | 2022 | |
| Livanova USA, INC. | $33.22 | 2022 | |
| Leo Pharma INC. | $23.68 | 2025 | Adbry |
| Incyte Corporation | $22.12 | 2025 | Opzelura |
| Catalyst Pharmaceuticals, INC. | $14.45 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madeline Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.